Washington Trust Advisors Inc. Has $11.77 Million Holdings in Edwards Lifesciences Corporation $EW

Washington Trust Advisors Inc. boosted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 5.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 138,005 shares of the medical research company’s stock after buying an additional 7,418 shares during the quarter. Edwards Lifesciences makes up 0.9% of Washington Trust Advisors Inc.’s holdings, making the stock its 27th largest holding. Washington Trust Advisors Inc.’s holdings in Edwards Lifesciences were worth $11,765,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of EW. Brighton Jones LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at $266,000. NewEdge Advisors LLC increased its holdings in Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after buying an additional 2,665 shares during the period. Sei Investments Co. increased its holdings in Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after buying an additional 58,988 shares during the period. Squarepoint Ops LLC increased its holdings in Edwards Lifesciences by 277.7% in the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after buying an additional 50,924 shares during the period. Finally, Treasurer of the State of North Carolina increased its holdings in Edwards Lifesciences by 0.4% in the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after buying an additional 1,065 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,177,507.96. This represents a 24.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 22,680 shares of the stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the sale, the vice president directly owned 21,266 shares in the company, valued at approximately $1,704,682.56. This represents a 51.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 88,096 shares of company stock valued at $7,288,799. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Stock Down 3.5%

EW opened at $79.86 on Friday. The firm’s 50-day simple moving average is $82.16 and its 200-day simple moving average is $82.74. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 4.42. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $87.89. The firm has a market cap of $45.98 billion, a price-to-earnings ratio of 42.48, a PEG ratio of 2.08 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the prior year, the firm earned $0.64 EPS. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the topic of several analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Mizuho set a $95.00 price target on shares of Edwards Lifesciences and gave the company an “outperform” rating in a report on Monday, April 13th. Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Finally, Piper Sandler reissued an “overweight” rating and issued a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $95.65.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.